Advanced search
1 file | 10.27 MB Add to list

Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures

(2021) CANCERS. 13(11).
Author
Organization
Abstract
Background: Blockade of the PD-1/PD-L1 pathway has revolutionized the oncology field in the last decade. However, the proportion of patients experiencing a durable response is still limited. In the current study, we performed an extensive immune monitoring in patients with stage III/IV melanoma and stage IV UC who received anti-PD-1 immunotherapy with SBRT. (2) Methods: In total 145 blood samples from 38 patients, collected at fixed time points before and during treatment, were phenotyped via high-parameter flow cytometry, luminex assay and UPLC-MS/MS. (3) Results: Baseline systemic immunity in melanoma and UC patients was different with a more prominent myeloid compartment and a higher neutrophil to lymphocyte ratio in UC. Proliferation (Ki67+) of CD8+ T-cells and of the PD-1+/PD-L1+ CD8+ subset at baseline correlated with progression free survival in melanoma. In contrast a higher frequency of PD-1/PD-L1 expressing non-proliferating (Ki67−) CD8+ and CD4+ T-cells before treatment was associated with worse outcome in melanoma. In UC, the expansion of Ki67+ CD8+ T-cells and of the PD-L1+ subset relative to tumor burden correlated with clinical outcome. (4) Conclusion: This study reveals a clearly different immune landscape in melanoma and UC at baseline, which may impact immunotherapy response. Signatures of proliferation in the CD8+ T-cell compartment prior to and early after anti-PD-1 initiation were positively correlated with clinical outcome in both cohorts. PD-1/PD-L1 expression on circulating immune cell subsets seems of clinical relevance in the melanoma cohort.
Keywords
Cancer Research, Oncology, immunotherapy, anti-PD-1, melanoma, urothelial cancer, immune monitoring, blood biomarkers, FDA APPROVAL, T-CELLS, EXPRESSION, MONOTHERAPY, NIVOLUMAB, THERAPY, BURDEN, PD-L1, PEMBROLIZUMAB, MULTICENTER

Downloads

  • 4564 21Meireson.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 10.27 MB

Citation

Please use this url to cite or link to this publication:

MLA
Meireson, Annabel, et al. “Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures.” CANCERS, vol. 13, no. 11, 2021, doi:10.3390/cancers13112630.
APA
Meireson, A., Tavernier, S., Van Gassen, S., Sundahl, N., Demeyer, A., Spaas, M., … Brochez, L. (2021). Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures. CANCERS, 13(11). https://doi.org/10.3390/cancers13112630
Chicago author-date
Meireson, Annabel, Simon Tavernier, Sofie Van Gassen, Nora Sundahl, Annelies Demeyer, Mathieu Spaas, Vibeke Kruse, et al. 2021. “Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures.” CANCERS 13 (11). https://doi.org/10.3390/cancers13112630.
Chicago author-date (all authors)
Meireson, Annabel, Simon Tavernier, Sofie Van Gassen, Nora Sundahl, Annelies Demeyer, Mathieu Spaas, Vibeke Kruse, Liesbeth Ferdinande, Jo Van Dorpe, Benjamin Hennart, Delphine Allorge, Filomeen Haerynck, Karel Decaestecker, Sylvie Rottey, Yvan Saeys, Piet Ost, and Lieve Brochez. 2021. “Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures.” CANCERS 13 (11). doi:10.3390/cancers13112630.
Vancouver
1.
Meireson A, Tavernier S, Van Gassen S, Sundahl N, Demeyer A, Spaas M, et al. Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures. CANCERS. 2021;13(11).
IEEE
[1]
A. Meireson et al., “Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures,” CANCERS, vol. 13, no. 11, 2021.
@article{8712821,
  abstract     = {{Background: Blockade of the PD-1/PD-L1 pathway has revolutionized the oncology field in the last decade. However, the proportion of patients experiencing a durable response is still limited. In the current study, we performed an extensive immune monitoring in patients with stage III/IV melanoma and stage IV UC who received anti-PD-1 immunotherapy with SBRT. (2) Methods: In total 145 blood samples from 38 patients, collected at fixed time points before and during treatment, were phenotyped via high-parameter flow cytometry, luminex assay and UPLC-MS/MS. (3) Results: Baseline systemic immunity in melanoma and UC patients was different with a more prominent myeloid compartment and a higher neutrophil to lymphocyte ratio in UC. Proliferation (Ki67+) of CD8+ T-cells and of the PD-1+/PD-L1+ CD8+ subset at baseline correlated with progression free survival in melanoma. In contrast a higher frequency of PD-1/PD-L1 expressing non-proliferating (Ki67−) CD8+ and CD4+ T-cells before treatment was associated with worse outcome in melanoma. In UC, the expansion of Ki67+ CD8+ T-cells and of the PD-L1+ subset relative to tumor burden correlated with clinical outcome. (4) Conclusion: This study reveals a clearly different immune landscape in melanoma and UC at baseline, which may impact immunotherapy response. Signatures of proliferation in the CD8+ T-cell compartment prior to and early after anti-PD-1 initiation were positively correlated with clinical outcome in both cohorts. PD-1/PD-L1 expression on circulating immune cell subsets seems of clinical relevance in the melanoma cohort.}},
  articleno    = {{2630}},
  author       = {{Meireson, Annabel and Tavernier, Simon and Van Gassen, Sofie and Sundahl, Nora and Demeyer, Annelies and Spaas, Mathieu and Kruse, Vibeke and Ferdinande, Liesbeth and Van Dorpe, Jo and Hennart, Benjamin and Allorge, Delphine and Haerynck, Filomeen and Decaestecker, Karel and Rottey, Sylvie and Saeys, Yvan and Ost, Piet and Brochez, Lieve}},
  issn         = {{2072-6694}},
  journal      = {{CANCERS}},
  keywords     = {{Cancer Research,Oncology,immunotherapy,anti-PD-1,melanoma,urothelial cancer,immune monitoring,blood biomarkers,FDA APPROVAL,T-CELLS,EXPRESSION,MONOTHERAPY,NIVOLUMAB,THERAPY,BURDEN,PD-L1,PEMBROLIZUMAB,MULTICENTER}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{22}},
  title        = {{Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures}},
  url          = {{http://doi.org/10.3390/cancers13112630}},
  volume       = {{13}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: